paliperidone

BEERS REMS

PO, IM: Acute and maintenance treatment of schizophrenia (Invega and Invega Sustenna).
IM: Maintenance treatment of schizophrenia after patients have been adequately treated with Invega Sustenna for at least 4 mo (Invega Trinza).
IM: Maintenance treatment of schizophrenia after patients have been adequately treated with either Invega Sustenna for at least 4 mo or Invega Trinza for at least one 3-mo cycle (Invega Hafyera).
PO, IM: Acute treatment of schizoaffective disorder (as monotherapy or as adjunct to mood stabilizers and/or antidepressants) (Invega and Invega Sustenna).

Contraindicated in:

Hypersensitivity to paliperidone or risperidone
Concurrent use of drugs known to cause QT interval prolongation (including quinidine, procainamide, sotalol, amiodarone, chlorpromazine, thioridazine, moxifloxacin)
History of congenital QTc prolongation or other cardiac arrhythmias
Bradycardia, hypokalemia, hypomagnesemia (↑ risk of QTc prolongation)
Pre-existing severe GI narrowing (due to nature of tablet formulation)
CCr <50 mL/min (for IM).

Use Cautiously in:

Patients with Parkinson's disease or dementia with Lewy Bodies (↑ sensitivity to effects of antipsychotics)
History of suicide attempt
History of HF, MI, conduction abnormalities, stroke, TIA (↑ risk of orthostatic hypotension and syncope)
Patients at risk for aspiration pneumonia or falls
History of seizures
Conditions which may ↑ body temperature (strenuous exercise, exposure to extreme heat, concurrent anticholinergics or risk of dehydration)
↓ GI transit time (may ↑ blood levels)
May mask symptoms of some drug overdoses, intestinal obstruction, Reye's Syndrome, or brain tumor (due to antiemetic effect)
Diabetes mellitus
Severe hepatic impairment
Renal impairment (dose ↓ recommended if CCr <80 mL/min)
Low white blood cell count/absolute neutrophil count or history of drug-induced leukopenia/neutropenia (↑ risk of leukopenia/neutropenia)
OB: Neonates at ↑ risk for extrapyramidal symptoms and withdrawal after delivery when exposed during the 3rd trimester; use only if maternal benefit outweighs fetal risk
Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
Pedi: Children <12 yr (safety and effectiveness not established)
Geri: Appears on Beers list. ↑ risk of stroke, cognitive decline, and mortality in older adults with dementia. Avoid use in older adults, except for schizophrenia.

CV: palpitations, tachycardia (dose related), QT interval prolongation, bradycardia, orthostatic hypotension.

EENT: blurred vision.

Endo: galactorrhea, gynecomastia, hyperglycemia.

GI: abdominal pain, dry mouth, dyspepsia, nausea, swollen tongue.

GU: ↓ fertility (females), amenorrhea, impotence, priapism.

Hemat: AGRANULOCYTOSIS, leukopenia, neutropenia.

Metab: dyslipidemia, weight gain.

MS: back pain, dystonia (dose related).

Neuro: drowsiness, extrapyramidal disorders (dose related), headache, insomnia, akathisia, anxiety, confusion, dizziness, dysarthria, fatigue, NEUROLEPTIC MALIGNANT SYNDROME, SEIZURES, syncope, tardive dyskinesia, tremor (dose related), weakness.

Resp: dyspnea, cough.

Misc: fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA).

Drug-Drug:

↑ risk of CNS depression with other CNS depressants including alcohol, antihistamines, sedative/hypnotics, or opioid analgesics.
May antagonize the effects of levodopa or other dopamine agonists.
↑ risk of orthostatic hypotension with antihypertensives, nitrates, or other agents that lower BP.
Strong CYP3A4 inducers or strong P-glycoprotein inducers, including carbamazepine or rifampin may ↓ levels/effects; avoid concurrent use with Invega Sustenna (if use of strong CYP3A4 or P-glycoprotein inducer necessary, consider using paliperidone ER tablets).
Valproic acid may ↑ levels (may need to ↓ dose of paliperidone)

Drug-Natural Products:

St. John's wort may ↓ levels/effects; avoid concurrent use with Invega Sustenna.

(Generic available)

Extended-release tablets (Invega): 1.5 mg; 3 mg; 6 mg; 9 mg;
Extended-release intramuscular injection (Invega Sustenna): 39 mg/0.25 mL; 50 mg/0.5 mL; 75 mg/0.75 mL; 78 mg/0.5 mL; 100 mg/mL; 117 mg/0.75 mL; 150 mg/1.5 mL; 156 mg/mL; 234 mg/1.5 mL;
Extended-release intramuscular injection (Invega Trinza): 175 mg/0.875 mL; 263 mg/1.315 mL; 273 mg/0.875 mL; 350 mg/1.75 mL; 410 mg/1.315 mL; 525 mg/2.625 mL; 546 mg/1.75 mL; 819 mg/2.625 mL;
Extended-release intramuscular injection (Invega Hafyera): 1,092 mg/3.5 mL; 1,560 mg/5 mL;

Schizophrenia

PO (Adults): 6 mg once daily; may titrate by 3 mg/day at intervals of at least 5 days (range 3–12 mg/day).
PO (Children 12–17 yr): 3 mg once daily; may titrate by 3 mg/day at intervals of at least 5 days (not to exceed 6 mg if <51 kg or 12 mg if ≥51 kg).
IM (Adults): Invega Sustenna: 234 mg initially, then 156 mg 1 wk later; continue with monthly maintenance dose of 117 mg (range of 39–234 mg based on efficacy and/or tolerability); Invega Trinza: Dose should be based on dose of previous 1-mo injection dose of Invega Sustenna. If last dose of Invega Sustenna was 78 mg: Administer 273 mg of Invega Trinza every 3 mo. If last dose of Invega Sustenna was 117 mg: Administer 410 mg of Invega Trinza every 3 mo. If last dose of Invega Sustenna was 156 mg: Administer 546 mg of Invega Trinza every 3 mo. If last dose of Invega Sustenna was 234 mg: Administer 819 mg of Invega Trinza every 3 mo. May adjust dose based on efficacy and/or tolerability (range: 273–819 mg). Invega Hafyera: Dose should be based on dose of previous 1-mo injection dose of Invega Sustenna or previous every 3-mo dose of Invega Trinza. If last dose of Invega Sustenna was 156 mg: Administer 1,092 mg of Invega Hafyera every 6 mo. If last dose of Invega Sustenna was 234 mg: Administer 1,560 mg of Invega Hafyera every 6 mo. If last dose of Invega Trinza was 546 mg: Administer 1,092 mg of Invega Hafyera every 6 mo. If last dose of Invega Trinza was 819 mg: Administer 1,560 mg of Invega Hafyera every 6 mo.

Renal Impairment

PO (Adults): CCr 50–79 mL/min: 3 mg/day initially; dose may be ↑ to maximum of 6 mg/day; CCr 10–<50 mL/min: 1.5 mg/day initially; dose may be ↑ to maximum of 3 mg/day.

Renal Impairment

IM (Adults): CCr 50–79 mL/min: Invega Sustenna: 156 mg initially, then 117 mg 1 wk later; continue with monthly maintenance dose of 78 mg; can adjust monthly maintenance dose to 39 mg, 78 mg, 117 mg, or 156 mg based on tolerability and response (max dose = 156 mg/month); Invega Trinza: once stabilized on Invega Sustenna, can then transition to appropriate dose of Invega Trinza (see above) CCr <50 mL/min: Contraindicated.

Schizoaffective Disorder

PO (Adults): 6 mg/day; may titrate by 3 mg/day at intervals of at least 4 days (range 3–12 mg/day).

Renal Impairment

PO (Adults): CCr 50–79 mL/min: 3 mg/day initially; dose may be ↑ to maximum of 6 mg/day; CCr 10–<50 mL/min: 1.5 mg/day initially; dose may be ↑ to maximum of 3 mg/day.

Invega, Invega Hafyera, Invega Sustenna, Invega Trinza

May act by antagonizing dopamine and serotonin in the CNS. Paliperidone is the active metabolite of risperidone.

Therapeutic Effects:

Decreased manifestations of schizophrenia.
Decreased manifestations of schizoaffective disorder.

Therapeutic Classification: antipsychotics

Pharmacologic Classification: benzisoxazoles

Absorption: 28% absorbed following oral administration, food ↑ absorption; slowly absorbed after IM administration (concentrations higher and more rapidly achieved with administration into deltoid muscle).

Distribution: Unknown.

Metabolism/Excretion: 59% excreted unchanged in urine; 32% excreted in urine as metabolites.

Half-life: PO: 23 hr; IM (Sustenna): 25–49 days; IM (Trinza): 84–139 days; IM (Hafyera): 148–159 days.

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
PO	unknown	24 hr	24 hr
IM —Sustenna	unknown	13 days	1 mo
IM —Trinza	unknown	30–33 days	3 mo
IM —Hafyera	unknown	29–32 days	6 mo

Instruct patient to take medication as directed. Advise patient that appearance of tablets in stool is normal and not of concern.
Inform patient of the possibility of extrapyramidal symptoms, neuroleptic malignant syndrome, and tardive dyskinesia. Instruct patient to report these symptoms immediately to health care professional.
Advise patient to change positions slowly to minimize orthostatic hypotension. Protect from falls.
May cause drowsiness and dizziness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
Advise patient and family to notify health care professional if thoughts about suicide or dying, attempts to commit suicide; new or worse depression; new or worse anxiety; feeling very agitated or restless; panic attacks; trouble sleeping; new or worse irritability; acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking, other unusual changes in behavior or mood occur.
Advise patient that extremes in temperature should also be avoided; this drug impairs body temperature regulation.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications, especially St. John's wort and alcohol.
Advise patient to seek nutritional, weight, or medical management as needed for weight gain or cholesterol elevation.
Instruct patient to notify health care professional promptly if sore throat, fever, unusual bleeding or bruising, rash, tremors, menstrual abnormalities, galactorrhea, or sexual dysfunction occur.
Advise patient to notify health care professional of medication regimen before treatment or surgery.
Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected, and to avoid breastfeeding. Encourage women who become pregnant while taking paliperidone to enroll in the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. Monitor neonates for extrapyramidal and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder) and manage symptoms appropriately. Monitor infants exposed to paliperidone through breast milk for excess sedation, failure to thrive, jitteriness, and extrapyramidal symptoms (tremors and abnormal muscle movements). May temporarily cause female infertility.
Emphasize the importance of routine follow-up exams to monitor side effects and continued participation in psychotherapy to improve coping skills.

pa-li-PER-i-done

NDC Code^*

0378- Mylan Pharmaceuticals Inc.
0378-3978- Paliperidone 0378-3978-93- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-3978-93)

0378- Mylan Pharmaceuticals Inc.
0378-3979- Paliperidone 0378-3979-93- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-3979-93)

0378- Mylan Pharmaceuticals Inc.
0378-3980- Paliperidone 0378-3980-93- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-3980-93)

0378- Mylan Pharmaceuticals Inc.
0378-3981- Paliperidone 0378-3981-93- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-3981-93)

0591- Actavis Pharma, Inc.
0591-3692- Paliperidone 0591-3692-10- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0591-3692-10)

0591- Actavis Pharma, Inc.
0591-3692- Paliperidone 0591-3692-19- 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0591-3692-19)

0591- Actavis Pharma, Inc.
0591-3692- Paliperidone 0591-3692-30- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0591-3692-30)

0591- Actavis Pharma, Inc.
0591-3693- Paliperidone 0591-3693-10- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0591-3693-10)

0591- Actavis Pharma, Inc.
0591-3693- Paliperidone 0591-3693-19- 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0591-3693-19)

0591- Actavis Pharma, Inc.
0591-3693- Paliperidone 0591-3693-30- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0591-3693-30)

0591- Actavis Pharma, Inc.
0591-3694- Paliperidone 0591-3694-10- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0591-3694-10)

0591- Actavis Pharma, Inc.
0591-3694- Paliperidone 0591-3694-19- 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0591-3694-19)

0591- Actavis Pharma, Inc.
0591-3694- Paliperidone 0591-3694-30- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0591-3694-30)

0591- Actavis Pharma, Inc.
0591-3695- Paliperidone 0591-3695-10- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0591-3695-10)

0591- Actavis Pharma, Inc.
0591-3695- Paliperidone 0591-3695-19- 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0591-3695-19)

0591- Actavis Pharma, Inc.
0591-3695- Paliperidone 0591-3695-30- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0591-3695-30)

0904- Major Pharmaceuticals
0904-6935- Paliperidone 0904-6935-61- 100 BLISTER PACK in 1 CARTON (0904-6935-61) > 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK

0904- Major Pharmaceuticals
0904-6936- Paliperidone 0904-6936-61- 100 BLISTER PACK in 1 CARTON (0904-6936-61) > 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK

0904- Major Pharmaceuticals
0904-6937- Paliperidone 0904-6937-61- 100 BLISTER PACK in 1 CARTON (0904-6937-61) > 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK

10147- Patriot Pharmaceuticals, LLC
10147-0951- Paliperidone 10147-0951-3- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (10147-0951-3)

10147- Patriot Pharmaceuticals, LLC
10147-0952- Paliperidone 10147-0952-1- 10 BLISTER PACK in 1 BOX, UNIT-DOSE (10147-0952-1) > 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK

10147- Patriot Pharmaceuticals, LLC
10147-0952- Paliperidone 10147-0952-3- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (10147-0952-3)

10147- Patriot Pharmaceuticals, LLC
10147-0953- Paliperidone 10147-0953-1- 10 BLISTER PACK in 1 BOX, UNIT-DOSE (10147-0953-1) > 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK

10147- Patriot Pharmaceuticals, LLC
10147-0953- Paliperidone 10147-0953-3- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (10147-0953-3)

10147- Patriot Pharmaceuticals, LLC
10147-0954- Paliperidone 10147-0954-1- 10 BLISTER PACK in 1 BOX, UNIT-DOSE (10147-0954-1) > 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK

10147- Patriot Pharmaceuticals, LLC
10147-0954- Paliperidone 10147-0954-3- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (10147-0954-3)

16714- NorthStar RxLLC
16714-866- Paliperidone 16714-866-01- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (16714-866-01)

16714- NorthStar RxLLC
16714-867- Paliperidone 16714-867-01- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (16714-867-01)

16714- NorthStar RxLLC
16714-868- Paliperidone 16714-868-01- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (16714-868-01)

16714- NorthStar RxLLC
16714-869- Paliperidone 16714-869-01- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (16714-869-01)

42292- Mylan Institutional Inc.
42292-026- Paliperidone 42292-026-20- 100 BLISTER PACK in 1 CARTON (42292-026-20) > 1 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK (42292-026-01)

42292- Mylan Institutional Inc.
42292-027- Paliperidone 42292-027-20- 100 BLISTER PACK in 1 CARTON (42292-027-20) > 1 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK (42292-027-01)

43975- Amerigen Pharmaceuticals, Inc.
43975-349- PALIPERIDONE 43975-349-03- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (43975-349-03)

43975- Amerigen Pharmaceuticals, Inc.
43975-350- PALIPERIDONE 43975-350-03- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (43975-350-03)

43975- Amerigen Pharmaceuticals, Inc.
43975-351- PALIPERIDONE 43975-351-03- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (43975-351-03)

43975- Amerigen Pharmaceuticals, Inc.
43975-352- PALIPERIDONE 43975-352-03- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (43975-352-03)

47335- Sun Pharmaceutical Industries, Inc.
47335-744- Paliperidone 47335-744-83- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (47335-744-83)

47335- Sun Pharmaceutical Industries, Inc.
47335-744- Paliperidone 47335-744-88- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (47335-744-88)

47335- Sun Pharmaceutical Industries, Inc.
47335-765- Paliperidone 47335-765-83- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (47335-765-83)

47335- Sun Pharmaceutical Industries, Inc.
47335-765- Paliperidone 47335-765-88- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (47335-765-88)

47335- Sun Pharmaceutical Industries, Inc.
47335-766- Paliperidone 47335-766-83- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (47335-766-83)

47335- Sun Pharmaceutical Industries, Inc.
47335-766- Paliperidone 47335-766-88- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (47335-766-88)

47335- Sun Pharmaceutical Industries, Inc.
47335-767- Paliperidone 47335-767-83- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (47335-767-83)

47335- Sun Pharmaceutical Industries, Inc.
47335-767- Paliperidone 47335-767-88- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (47335-767-88)

49252- Inventia Healthcare Limited
49252-032- PALIPERIDONE 49252-032-10- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (49252-032-10)

49252- Inventia Healthcare Limited
49252-033- PALIPERIDONE 49252-033-10- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (49252-033-10)

49252- Inventia Healthcare Limited
49252-034- PALIPERIDONE 49252-034-10- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (49252-034-10)

49252- Inventia Healthcare Limited
49252-035- PALIPERIDONE 49252-035-10- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (49252-035-10)

50458- Janssen Pharmaceuticals, Inc.
50458-550- INVEGA 50458-550-01- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (50458-550-01)

50458- Janssen Pharmaceuticals, Inc.
50458-550- INVEGA 50458-550-10- 10 BLISTER PACK in 1 BOX, UNIT-DOSE (50458-550-10) > 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK

50458- Janssen Pharmaceuticals, Inc.
50458-550- INVEGA 50458-550-98- 7 TABLET, EXTENDED RELEASE in 1 BOTTLE (50458-550-98)

50458- Janssen Pharmaceuticals, Inc.
50458-551- INVEGA 50458-551-01- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (50458-551-01)

50458- Janssen Pharmaceuticals, Inc.
50458-551- INVEGA 50458-551-10- 10 BLISTER PACK in 1 BOX, UNIT-DOSE (50458-551-10) > 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK

50458- Janssen Pharmaceuticals, Inc.
50458-551- INVEGA 50458-551-98- 7 TABLET, EXTENDED RELEASE in 1 BOTTLE (50458-551-98)

50458- Janssen Pharmaceuticals, Inc.
50458-552- INVEGA 50458-552-01- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (50458-552-01)

50458- Janssen Pharmaceuticals, Inc.
50458-552- INVEGA 50458-552-10- 10 BLISTER PACK in 1 BOX, UNIT-DOSE (50458-552-10) > 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK

50458- Janssen Pharmaceuticals, Inc.
50458-552- INVEGA 50458-552-98- 7 TABLET, EXTENDED RELEASE in 1 BOTTLE (50458-552-98)

50458- Janssen Pharmaceuticals, Inc.
50458-554- INVEGA 50458-554-01- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (50458-554-01)

50458- Janssen Pharmaceuticals, Inc.
50458-554- INVEGA 50458-554-10- 10 BLISTER PACK in 1 BOX, UNIT-DOSE (50458-554-10) > 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK

60687- American Health Packaging
60687-459- Paliperidone 60687-459-01- 100 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-459-01) > 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (60687-459-11)

60687- American Health Packaging
60687-470- Paliperidone 60687-470-01- 100 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-470-01) > 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (60687-470-11)

65162- Amneal Pharmaceuticals LLC
65162-280- Paliperidone 65162-280-03- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (65162-280-03)

65162- Amneal Pharmaceuticals LLC
65162-280- Paliperidone 65162-280-09- 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (65162-280-09)

65162- Amneal Pharmaceuticals LLC
65162-281- Paliperidone 65162-281-03- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (65162-281-03)

65162- Amneal Pharmaceuticals LLC
65162-281- Paliperidone 65162-281-09- 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (65162-281-09)

65162- Amneal Pharmaceuticals LLC
65162-282- Paliperidone 65162-282-03- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (65162-282-03)

65162- Amneal Pharmaceuticals LLC
65162-282- Paliperidone 65162-282-09- 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (65162-282-09)

65162- Amneal Pharmaceuticals LLC
65162-283- Paliperidone 65162-283-03- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (65162-283-03)

65162- Amneal Pharmaceuticals LLC
65162-283- Paliperidone 65162-283-09- 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (65162-283-09)

70518- REMEDYREPACK INC.
70518-0850- Paliperidone 70518-0850-0- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (70518-0850-0)

70518- REMEDYREPACK INC.
70518-0850- Paliperidone 70518-0850-1- 30 POUCH in 1 BOX (70518-0850-1) > 1 TABLET, EXTENDED RELEASE in 1 POUCH (70518-0850-2)

70518- REMEDYREPACK INC.
70518-2034- Paliperidone 70518-2034-0- 30 POUCH in 1 BOX (70518-2034-0) > 1 TABLET, EXTENDED RELEASE in 1 POUCH (70518-2034-1)

70518- REMEDYREPACK INC.
70518-2197- Paliperidone 70518-2197-0- 30 POUCH in 1 BOX (70518-2197-0) > 1 TABLET, EXTENDED RELEASE in 1 POUCH (70518-2197-1)

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Availability ⬆ ⬇

Route/Dosage ⬆ ⬇

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Classifications ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

Code ⬆